SCHEMBL18136752

SCHEMBL18136752

Cc1nc2cc(-c3c[nH]c4ncccc34)ccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 10/20 0.56
PRKCI P41743 1/20 0.55
DYRK1B Q9Y463 2/20 0.53
CDC7 O00311 6/20 0.52
ROCK2 O75116 2/20 0.52
MAP4K4 O95819 2/20 0.52
PIM1 P11309 2/20 0.52
PRKACA P17612 2/20 0.52
CDK2 P24941 2/20 0.52
GSK3B P49841 2/20 0.52
HIPK2 Q9H2X6 2/20 0.52
CLK4 Q9HAZ1 2/20 0.52
IRAK4 Q9NWZ3 1/20 0.52
BRD4 O60885 1/20 0.49
DAPK3 O43293 1/20 0.48
PRKD3 O94806 1/20 0.48
PAK4 O96013 1/20 0.48
FLT3 P36888 1/20 0.48
CSNK1A1 P48729 1/20 0.48
CLK2 P49760 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18136619 0.85 DYRK1A (0.54) DYRK1ADYRK1BCDC7ROCK2MAP4K4
SCHEMBL18136944 0.79 DYRK1B (0.57) DYRK1APRKCIDYRK1BCDC7ROCK2
SCHEMBL18136754 0.79 KIT (0.50) DYRK1A
SCHEMBL26174558 0.77 DYRK1B (0.69) DYRK1ADYRK1BCDC7ROCK2MAP4K4
SCHEMBL18136895 0.77 DYRK1B (0.55) DYRK1ADYRK1BCDC7ROCK2MAP4K4
SCHEMBL13302170 0.76 DYRK1A (0.61) DYRK1ADYRK1BCDC7ROCK2MAP4K4
SCHEMBL20292991 0.76 DYRK1B (0.67) DYRK1ADYRK1BCDC7ROCK2MAP4K4
SCHEMBL5306795 0.75 RAB9A (0.48) DYRK1APRKCICLK4
SCHEMBL18136860 0.74 DYRK1A (0.55) DYRK1ADYRK1BCDC7ROCK2MAP4K4
SCHEMBL15397131 0.74 DYRK1A (0.61) DYRK1ADYRK1BCDC7ROCK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10160755-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2018-12-25 US claimed
US-20160326162-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2016-11-10 US claimed
US-10160755-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2018-12-25 US disclosed
US-20160326162-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2016-11-10 US disclosed
US-20160326162-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2016-11-10 US disclosed
US-20160326162-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2016-11-10 US disclosed
WO-2016164641-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2016-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160755-B2 Compounds and methods for kinase modulation, and indications therefor MAP3K11, MAP4K2, PLK1 DYRK1A 395/4885PRKCI 90/4885DYRK1B 390/4885
US-20160326162-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K11, MAP4K2, PLK1 DYRK1A 395/4885PRKCI 90/4885DYRK1B 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.